Indian Court Blocks Sinopharm Weiqida Over Centrient's Amoxicillin

India’s High Court in Delhi has issued an injunction restraining China’s Sinopharm Weiqida from exporting, importing and selling its amoxicillin trihydrate in India, as it infringes Centrient’s patent. Sinopharm Weiqida has also been found guilty of contempt of court for failing to follow a preliminary injunction order that was issued in April 2017.

BrickWall
Sinopharm Weiqida has been blocked from selling amoxicillin in India • Source: Shutterstock

Centrient Pharmaceuticals has announced that the Delhi High Court in India has granted an injunction against China’s Sinopharm Weiqida Pharmaceutical blocking the export, import and sale into India of its amoxicillin trihydrate active pharmaceutical ingredient (API) in any form.

Sinopharm Weiqida was also found to be prima facie in contempt of the Delhi High Court’s original preliminary injunction order,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin